Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
Alexander T CohenKatherine J CreeperRaza AlikhanChaozer ErJean M ConnorsMenno V HuismanAndres MunozGiorgio VescovoRupert M BauersachsWalter AgenoGiancarlo AgnelliCecilia BecattiniPublished in: Thrombosis and haemostasis (2024)
The frequencies of recurrent VTE and major bleeding events at 7, 30, and 90 days of apixaban compared with dalteparin were similar in patients with cancer-associated VTE. This supports the use of apixaban for the initiation and early phase of anticoagulant therapy in cancer-associated VTE.